Are TSI’s cells/acquired IND/trial mentioned?
When will TSI be granted the bright spotlight they deserve…
Interesting article, here’s a few pull quotes…
“In addition to these case reports and clinical studies, three research groups have demonstrated outcomes from a more strictly designed phase I/II double-blind RCT. Giacomo et al. tested a single-center, double-blind, phase 1/2a, RCT of UC-MSC infusions in treatment of 12 COVID-19 ARDS patients compared with 12 patients who received two infusions of vehicle. Patients in these two groups received comparable standard care. There was no significant difference in infusion-associated AEs between these two groups, and no serious AEs that are linked to UC-MSC infusion were observed; this indicates the safety of UC-MSC infusions. UC-MSC treatment was associated with significantly improved patient survival, SAEs (SAE)-free survival, and time to recovery.”
“MSCs are considered to be a candidate for treating CSS and repairing damaged lung tissues due to their multiple potent activities, including anti-inflammation, immunomodulation, and ability to secrete soluble vesicles and multiple growth factors. Promising outcomes have been reported from ongoing clinical trials involving MSC treatment for COVID-19: (1) patients were safe and well-tolerated after treatment with MSCs that were generated from various sources with a wide range of doses, (2) improvements were observed in patients after MSCs treatment, such as through decreasing circulating levels of pro-inflammatory cytokines and laboratory parameters, better lung inflammation absorption, and (3) MSCs-treated patients had faster increase in SpO2, a shorter hospital stay, and a higher survival rate. However, some scientific and clinical questions remain to be addressed. For example, what are the exact mechanisms underlying the MSCs’ treatment of COVID-19 patients? Which source of MSCs is the best for this treatment? At which stage will COVID-19 patients have the best outcomes as a result of MSCs treatment? Are there any COVID-19 patients who should not receive MSCs treatment? Can MSCs treatment reduce the long-term residual adverse effects associated with COVID-19 infection? In addition, will the combinatory therapy of MSCs with other supportive drugs work better than the single use of each individual treatment? Apart from cell-based therapy, exosome vesicles, and secretome of MSCs can be considered as an alternative. However, limitations of these closed trials were also acknowledged. For example, most of these trials had a small sample size and were single-arm or parallel control; they lacked a strict design such as the double-blind, randomized, placebo control with multiple centers. Also, the main and secondary evaluation criteria were not uniform, and the long-term follow-up was not carried out.”
You don’t say….
Conclusions
The general mechanisms of action of MSCs include immunomodulation and tissue repair capability (antifibrosis and angiogenesis), and current preliminary clinical results of MSC-based therapies have shown some favorable outcomes[100% SURVIVAL HELLO!!!] for severe and critically severe COVID-19 patients, thus making it a promising therapy[YA THINK?!?]. However, double blind RCTs with large sample sizes are still required to thoroughly examine the safety and efficacy of MSCs [
GETTING THERE FOLKS!] and each specific MSC product [JADICELL IS KING]. Nevertheless, MSC-based therapies during a global pandemic brings hope [BINGO!!] to combating COVID-19 and in meeting urgent [
] medical needs, although a variety of challenges still lay ahead.Bring on the JadiCell Phase III Trial/Results then revisit the content available via UC-MSC/ARDS/COVID TSOI
Boy…can’t wait.
I bet…..